Search
Taraxacum officinale leaf
go.drugbank.com/drugs/DB14342InvestigationalTaraxacum officinale leaf is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Mixtures: Tea BagsSafrazine
go.drugbank.com/drugs/DB09253ApprovedWithdrawnIn 1960, it was used as an antidepressant but it is now discontinued.
Tranilast
go.drugbank.com/drugs/DB07615InvestigationalIt has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis. … In 1982, it was approved in Japan and South Korea for the management of bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993.
Sulopenem etzadroxil
go.drugbank.com/drugs/DB16335ApprovedInvestigational[L51768] Sulopenem etzadroxil was approved by the FDA in October 2024 for the treatment of uncomplicated urinary tract infections.
Pegloticase
go.drugbank.com/drugs/DB09208ApprovedInvestigational[L42425] Pegloticase has a similar activity to rasburicase, an enzyme that metabolizes uric acid to allantoin. … [L42425] Pegloticase has a longer terminal elimination half-life thanks to the addition of a polyethylene glycol (PEG) group.
Thiopental
go.drugbank.com/drugs/DB00599ApprovedInvestigationalVet approvedWithdrawnIt has been used in neurosurgical patients to reduce increased intracranial pressure. It does not produce any excitation but has poor analgesic and muscle relaxant properties.
Products: Pentothal Inj 500mg/syrPipotiazine
go.drugbank.com/drugs/DB01621ApprovedInvestigationalWithdrawnPipotiazine has actions similar to those of other phenothiazines.
Debrisoquine
go.drugbank.com/drugs/DB04840ApprovedThey are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
Dutasteride
go.drugbank.com/drugs/DB01126ApprovedInvestigationalDutasteride was approved by the FDA in 2001 for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men as monotherapy or in combination with the α-adrenergic antagonist [tamsulosin] to … However, unlike finasteride, dutasteride is not yet indicated for the treatment of androgenic alopecia although it was demonstrated to be effective in several randomized, double-blind, placebo-controlled
Synonyms: (5α,17β)-N-(2,5-bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamideEfgartigimod alfa
go.drugbank.com/drugs/DB15270ApprovedInvestigationalEfgartigimod alfa for intravenous use was granted FDA approval on December 17, 2021[L39501] and European Commission approval on August 11, 2022 for use in patients with myasthenia gravis. … [L43190] A formulation for subcutaneous use that combines efgartigimod alfa and hyaluronidase was later approved for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP